By using reverse translational studies that exploited the use of CD73−/− mice and syngeneic glioma models, they were able to show that the absence of the molecule significantly improved survival, especially after treatment with PD-1 and CTLA-4 inhibitors, suggesting a new possible target, CD73, to improve the response to therapy ICI [208]. This evidence concerns the gene NT5E and central nervous system cancer.